Literature DB >> 20218878

CD4 T cell count reconstitution in HIV controllers after highly active antiretroviral therapy.

Jason F Okulicz1, Greg A Grandits, Amy C Weintrob, Michael L Landrum, Anuradha Ganesan, Nancy F Crum-Cianflone, Brian K Agan, Vincent C Marconi.   

Abstract

Sixty-two human immunodeficiency virus (HIV) controllers (6 elite and 56 viremic controllers) in the US Military Department of Defense HIV Natural History Study cohort initiated highly active antiretroviral therapy (HAART) and achieved statistically significant mean CD4 cell count increases, although the gains were lower than those in treated noncontrollers. HIV controllers experienced CD4 cell count reconstitution with HAART regardless of pretherapy viral load, including patients with undetectable viral loads at HAART initiation.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20218878     DOI： 10.1086/651421

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  22 in total

1.  Antiretroviral therapy in HIV-infected elite controllers: impact on gut immunology, microbial translocation, and biomarkers of serious non-AIDS conditions.

Authors:  Connie J Kim; Colin Kovacs; Tae-Wook Chun; Gabor Kandel; Brendan J W Osborne; Sanja Huibner; Kamnoosh Shahabi; Feng-Yun Yue; Erika Benko; Mario Ostowski; Rupert Kaul
Journal:  J Acquir Immune Defic Syndr       Date:  2014-12-15       Impact factor: 3.731

Review 2.  HIV controllers: a multifactorial phenotype of spontaneous viral suppression.

Authors:  Jacques Thèze; Lisa A Chakrabarti; Benoît Vingert; Filippos Porichis; Daniel E Kaufmann
Journal:  Clin Immunol       Date:  2011-08-04       Impact factor: 3.969

3.  Hospitalization Rates and Reasons Among HIV Elite Controllers and Persons With Medically Controlled HIV Infection.

Authors:  Trevor A Crowell; Kelly A Gebo; Joel N Blankson; P Todd Korthuis; Baligh R Yehia; Richard M Rutstein; Richard D Moore; Victoria Sharp; Ank E Nijhawan; W Christopher Mathews; Lawrence H Hanau; Roberto B Corales; Robert Beil; Charurut Somboonwit; Howard Edelstein; Sara L Allen; Stephen A Berry
Journal:  J Infect Dis       Date:  2014-12-15       Impact factor: 5.226

4.  Effect of baseline HIV disease parameters on CD4+ T cell recovery after antiretroviral therapy initiation in Kenyan women.

Authors:  Lyle R McKinnon; Makobu Kimani; Charles Wachihi; Nico J Nagelkerke; Festus K Muriuki; Anthony Kariri; Richard T Lester; Lawrence Gelmon; T Blake Ball; Francis A Plummer; Rupert Kaul; Joshua Kimani
Journal:  PLoS One       Date:  2010-07-02       Impact factor: 3.240

5.  Effect of antiretroviral therapy on HIV reservoirs in elite controllers.

Authors:  Tae-Wook Chun; J Shawn Justement; Danielle Murray; Connie J Kim; Jana Blazkova; Claire W Hallahan; Erika Benko; Cecilia T Costiniuk; Gabor Kandel; Mario Ostrowski; Rupert Kaul; Susan Moir; Joseph P Casazza; Richard A Koup; Colin Kovacs; Anthony S Fauci
Journal:  J Infect Dis       Date:  2013-07-11       Impact factor: 5.226

6.  Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers.

Authors:  Jonathan Z Li; Florencia P Segal; Ronald J Bosch; Christina M Lalama; Carla Roberts-Toler; Heloise Delagreverie; Rachel Getz; Pilar Garcia-Broncano; Jennifer Kinslow; Randall Tressler; Cornelius N Van Dam; Michael Keefer; Mary Carrington; Mathias Lichterfeld; Daniel Kuritzkes; Xu G Yu; Alan Landay; Paul E Sax
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

7.  Lessons to be Learned from Natural Control of HIV - Future Directions, Therapeutic, and Preventive Implications.

Authors:  David Shasha; Bruce D Walker
Journal:  Front Immunol       Date:  2013-06-25       Impact factor: 7.561

8.  Disease Progression in HIV-1-Infected Viremic Controllers.

Authors:  Katherine C Groves; David F Bibby; Duncan A Clark; Are Isaksen; Jane R Deayton; Jane Anderson; Chloe Orkin; Andrew J Stagg; Aine McKnight
Journal:  J Acquir Immune Defic Syndr       Date:  2012-12-01       Impact factor: 3.731

9.  Current Treatment Options for HIV Elite Controllers: a Review.

Authors:  Katherine Promer; Maile Y Karris
Journal:  Curr Treat Options Infect Dis       Date:  2018-04-16

10.  Antiretroviral therapy for HIV controllers: Reasons for initiation and outcomes in the French ANRS-CO21 CODEX cohort.

Authors:  Léo Plaçais; Faroudy Boufassa; Camille Lécuroux; Elise Gardiennet; Véronique Avettand-Fenoel; Asier Saez-Cirion; Olivier Lambotte; Nicolas Noël
Journal:  EClinicalMedicine       Date:  2021-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.